Hypocalcemia Post Denosumab in Patients with Chronic Kidney Disease Stage 4-5
- 18 March 2015
- journal article
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 41 (2), 129-137
- https://doi.org/10.1159/000380960
Abstract
Background: Denosumab, a RANK-ligand inhibitor, is an effective treatment for osteoporosis in postmenopausal women and men. Unlike the bisphosphonates, it is not excreted by the kidney. Little is known, however, about its efficacy and safety in patients with severe chronic kidney disease (CKD). Methods: A retrospective study was performed in CKD 4-5D patients from a tertiary referral hospital who were treated with denosumab between 1st January 2011 and 31st March 2014. Data collected included information about the following: CKD stage, fracture history, bone mineral density, serum calcium levels pre and post denosumab treatment, episodes of hypocalcemia, relevant medications and adverse events. Results: Eight patients with CKD-5 and 6 patients with CKD-4 were identified (all female, mean age 77.1 ± 9.9). The mean pre-denosumab calcium value was 2.42 ± 0.12 mmol/l, PTH 20.2 ± 14.7 pmol/l and 25-OH vitamin D 69.1 ± 30.1 nmol/l. After denosumab treatment, 6/8 patients with CKD-5/5D, and 2/5 patients with CKD-4 developed severe hypocalcemia. Two patients developed direct adverse complications of hypocalcemia (seizure, laryngospasm, prolonged QTc). Among the patients who developed hypocalcemia, the median time to serum calcium nadir was 21 days and the median time to correction of hypocalcemia was 71 days. Treatment of hypocalcemia required large doses of oral calcium and calcitriol, and increases in dialysate calcium concentration. Conclusions: A high rate of severe hypocalcemia was observed in patients with advanced CKD treated with denosumab. If denosumab is used in patients with severe CKD, close monitoring and aggressive replacement of calcium and calcitriol is required to avoid the development of hypocalcemia.Keywords
This publication has 20 references indexed in Scilit:
- Women and CKD-Mineral and Bone DisorderAdvances in Chronic Kidney Disease, 2013
- A single-dose study of denosumab in patients with various degrees of renal impairmentJournal of Bone and Mineral Research, 2012
- Effects of denosumab on fracture and bone mineral density by level of kidney functionJournal of Bone and Mineral Research, 2011
- Management of Osteoporosis in CKD Stages 3 to 5American Journal of Kidney Diseases, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisThe New England Journal of Medicine, 2009
- ForewordKidney International, 2009
- Bisphosphonates in Chronic Kidney Disease; Balancing Potential Benefits and Adverse Effects on Bone and Soft TissueClinical Journal of the American Society of Nephrology, 2009
- Endocrinology and Dialysis Jean L. Holley, Series Editor: Osteoporosis and Chronic Kidney DiseaseSeminars in Dialysis, 2007
- Fellows ’ Forum: Hip Fractures in End-Stage Renal Disease Patients: IncidenceRisk Factorsand PreventionSeminars in Dialysis, 2006
- Hypocalcemic CardiomyopathySocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1980